Two different immune related adverse events occured at pancreas after nivolumab in an advanced RCC patient.

Abstract

INTRODUCTION\nThe foremost side effects of anti-PD-1 therapy are immune related and pancreatitis associated with nivolumab treatment has been rarely reported.\n\n\nCASE REPORT\nThe patient was treating with subcutaneous insulin because of nivolumab induced diabetes mellitus. A patient was diagnosed metastatic renal cell carcinoma and treated with nivolumab. Diabetes mellitus and pancreatitis, which are immune-related adverse events were observed in the patient.\n\n\nMANAGEMENT & OUTCOME\nAfter the diagnosis of nivolumab induced immune pancreatitis methylprednisolone 2\u2009mg/kg per day intravenously started. After steroid treatment, the patient s complaints regressed, amylase and lipase levels began to decline.\n\n\nDISCUSSION\nThis case report highlights the possibility of different immune-related adverse events that can affect pancreas in all patients which were treated with ICIs.